Diligence memo · auto-generated · as of July 2, 2026
Verseau Therapeutics, Inc.
Verseau Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Verseau Therapeutics, Inc. operates in Pharma, based in Auburndale.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Verseau Therapeutics, Inc. has raised $4.3M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.3M on 2017-03-15.
Most recent recorded round closed around 2017-03-15.
Valuation (modeled)modeled
Provath models Verseau Therapeutics, Inc. at approximately $133M (range $4.9M–$724M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.73× the median modeled value of Series A Pharma companies in 2016–2018 (14 peers) — value vs value, same stage and era. Within the normal band (73% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 9.3 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 53% of Pharma peers (310 compared).
Modeled value ranks above 71% of those peers.
Closest niche peers: Qool Therapeutics, Inc., SpringWorks Therapeutics, LLC, Caliber Therapeutics, Inc., Rodin Therapeutics, Inc., SmartPharm Therapeutics, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.